Monopar Therapeutics (MNPR) Institutional Ownership $40.69 -0.49 (-1.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$40.56 -0.13 (-0.31%) As of 08/1/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Monopar Therapeutics (NASDAQ:MNPR)CurrentInstitutional OwnershipPercentage1.83%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$59.18MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.07M Get MNPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Monopar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MNPR Institutional Buying and Selling by Quarter Monopar Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/31/2025 AlphaQuest LLC1,784$64K0.0%+46.8%0.029% 6/27/2025Goldman Sachs Group Inc.18,480$673K0.0%N/A0.302% 5/19/2025Jane Street Group LLC10,357$377K0.0%N/A0.169% 5/16/2025Goldman Sachs Group Inc.18,480$673K0.0%N/A0.302% 5/16/2025ADAR1 Capital Management LLC100,774$3.67M0.7%-22.5%1.648% 5/15/2025OMERS ADMINISTRATION Corp9,000$328K0.0%N/A0.147% 5/14/2025Affinity Asset Advisors LLC62,000$2.26M0.2%N/A1.014% 5/14/2025 AlphaQuest LLC1,215$44K0.0%N/A0.020% 4/23/2025 Gerber LLC5,601$204K0.2%N/A0.092% 2/17/2025Point72 Asset Management L.P.167,892$3.69M0.0%N/A2.752% 2/17/2025Janus Henderson Group PLC1,046,899$23.44M0.0%N/A17.162% 2/14/2025RA Capital Management L.P.511,207$11.25M0.1%N/A8.380% 2/14/2025Adage Capital Partners GP L.L.C.599,195$13.18M0.0%N/A9.823% 2/13/2025ADAR1 Capital Management LLC130,037$2.86M0.6%N/A2.132% 2/12/2025Geode Capital Management LLC38,596$849K0.0%+174.4%0.633% 2/12/2025JPMorgan Chase & Co.2,037$45K0.0%N/A0.033% 10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635% 8/13/2021Geode Capital Management LLC28,761$169K0.0%+9.0%0.229% 8/13/2021Vanguard Group Inc.97,462$574K0.0%+116.2%0.775% 5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073% 5/12/2021Northern Trust Corp36,001$223K0.0%-38.8%0.286% 5/12/2021Geode Capital Management LLC26,394$163K0.0%N/A0.210% (Data available from 1/1/2016 forward) MNPR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MNPR shares? During the previous two years, 14 institutional investors and hedge funds held shares of Monopar Therapeutics. The most heavily invested institutionals were Janus Henderson Group PLC ($23.44M), Adage Capital Partners GP L.L.C. ($13.18M), RA Capital Management L.P. ($11.25M), Point72 Asset Management L.P. ($3.69M), ADAR1 Capital Management LLC ($3.67M), Affinity Asset Advisors LLC ($2.26M), and Geode Capital Management LLC ($849K).Learn more on Monopar Therapeutics' institutional investors. What percentage of Monopar Therapeutics' stock is owned by institutional investors? 1.83% of Monopar Therapeutics' stock is owned by institutional investors. Learn more on MNPR's institutional investor holdings. Which institutional investors have been buying Monopar Therapeutics' stock? Of the 14 institutional investors that purchased Monopar Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Janus Henderson Group PLC ($1.05M), Adage Capital Partners GP L.L.C. ($599.20K), RA Capital Management L.P. ($511.21K), Point72 Asset Management L.P. ($167.89K), ADAR1 Capital Management LLC ($130.04K), Windsor Advisory Group LLC ($89.97K), and Affinity Asset Advisors LLC ($62K). How much institutional buying is happening at Monopar Therapeutics? Institutional investors have bought a total of 2,607,499 shares in the last 24 months. This purchase volume represents approximately $59.18M in transactions. Which of Monopar Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Monopar Therapeutics stock in the last 24 months: ADAR1 Capital Management LLC ($29.26K). How much institutional selling is happening at Monopar Therapeutics? Institutional investors have sold a total of 29,263 shares in the last 24 months. This volume of shares sold represents approximately $1.07M in transactions. Related Companies Arcus Biosciences Major Shareholders Pharvaris Major Shareholders Spyre Therapeutics Major Shareholders Avadel Pharmaceuticals Major Shareholders Amphastar Pharmaceuticals Major Shareholders Iovance Biotherapeutics Major Shareholders Enliven Therapeutics Major Shareholders Anavex Life Sciences Major Shareholders Structure Therapeutics Major Shareholders Ardelyx Major Shareholders This page (NASDAQ:MNPR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts